The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASH
Honoraria - Abbvie; Blueprint Medicines; Celgene; DAVA Pharmaceuticals; Incyte; LFB Biotechnologies; MustangBio; Novartis; Pacylex; Roche Molecular Diagnostics; Stemline Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Celgene; Incyte; LFB Biotechnologies; MustangBio; Novartis; Pacylex; Roche Molecular Diagnostics; Stemline Therapeutics
Research Funding - Abbvie; Affymetrix/Thermo Fisher Scientific; Cellectis; Daiichi Sankyo; Novartis; Plexxikon; Samus Therapeutics; Stemline Therapeutics
Travel, Accommodations, Expenses - Abbvie; Celgene; DAVA Pharmaceuticals; mustangbio; Stemline Therapeutics
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Jingbo Yu
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Shreekant Parasuraman
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Dilan Paranagama
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Jonathan Kish
Employment - Cardinal Health
Research Funding - Incyte
 
Jay Visaria
Employment - HealthCore
Research Funding - Incyte
 
Mukul Singhal
Employment - HealthCore
Research Funding - Incyte
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Pragmatist; Sierra Oncology
Research Funding - Blueprint Medicines; Celgene; CTI BioPharma Corp; Genentech; Gilead Sciences; Incyte; Novartis; NS Pharma; Promedior; Roche
 
Aaron Thomas Gerds
Stock and Other Ownership Interests - Samus Therapeutics
Consulting or Advisory Role - Apexx Oncology; AstraZeneca/MedImmune; Celgene; CTI; Incyte
Research Funding - Celgene; CTI; Gilead Sciences; Imago Biosciences; Incyte; Pfizer; Roche/Genentech; Sierra Oncology